230 related articles for article (PubMed ID: 2522336)
1. Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.
Booth RF; Honey AC; Lad N; Tuffin DP; Wade PJ
Br J Pharmacol; 1989 Feb; 96(2):395-405. PubMed ID: 2522336
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
Mallarkey G; Smith GM
Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
[TBL] [Abstract][Full Text] [Related]
3. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
7. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
Cook NS; Bruttger O; Pally C; Hagenbach A
Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
[TBL] [Abstract][Full Text] [Related]
8. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
9. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
10. Effect of SC 38249, a novel substituted imidazole, on platelet aggregation in vitro and in vivo.
Lad N; Honey AC; Lunt DO; Booth RF; Westwick J; Manley PW; Tuffin DP
Thromb Haemost; 1988 Apr; 59(2):164-70. PubMed ID: 3133807
[TBL] [Abstract][Full Text] [Related]
11. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
Kakushi H; Shike T; Uchida K
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):171-8. PubMed ID: 2731807
[TBL] [Abstract][Full Text] [Related]
12. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist.
Ford-Hutchinson AW; Girard Y; Lord A; Jones TR; Cirino M; Evans JF; Gillard J; Hamel P; Leveillé C; Masson P
Can J Physiol Pharmacol; 1989 Sep; 67(9):989-93. PubMed ID: 2598135
[TBL] [Abstract][Full Text] [Related]
14. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
Dubé GP; Jakubowski JA; Brune KA; Bemis KG; Kurtz WL
J Pharmacol Exp Ther; 1995 Feb; 272(2):799-807. PubMed ID: 7853197
[TBL] [Abstract][Full Text] [Related]
16. Human recombinant phospholipase A2 inhibits platelet aggregation in vitro and in vivo in rat and guinea pig.
Cirino G; Cicala C; Sorrentino R; Sorrentino L; Browning JL; Page CP
Eur J Pharmacol; 1994 Feb; 252(2):147-54. PubMed ID: 8157055
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
18. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
Darius H; Smith JB; Lefer AM
J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428
[TBL] [Abstract][Full Text] [Related]
20. Effects of thromboxane antagonist EP 045 on platelet aggregation.
Jones RL; Wilson NH; Armstrong RA; Peesapati V; Smith GM
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():345-50. PubMed ID: 6303074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
